- Home
- UBS vs SNY Comparison
UBS vs SNY Comparison
Compare UBS & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBS
- SNY
- Stock Information
- Founded
- UBS 1862
- SNY 1994
- Country
- UBS Switzerland
- SNY France
- Employees
- UBS N/A
- SNY N/A
- Industry
- UBS Major Banks
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- UBS Finance
- SNY Health Care
- Exchange
- UBS Nasdaq
- SNY Nasdaq
- Market Cap
- UBS 101.3B
- SNY 120.2B
- IPO Year
- UBS N/A
- SNY N/A
- Fundamental
- Price
- UBS $29.79
- SNY $47.71
- Analyst Decision
- UBS Buy
- SNY Buy
- Analyst Count
- UBS 2
- SNY 2
- Target Price
- UBS N/A
- SNY $57.50
- AVG Volume (30 Days)
- UBS 1.3M
- SNY 2.7M
- Earning Date
- UBS 02-04-2025
- SNY 01-30-2025
- Dividend Yield
- UBS 3.53%
- SNY 4.27%
- EPS Growth
- UBS N/A
- SNY N/A
- EPS
- UBS 1.35
- SNY 4.00
- Revenue
- UBS $47,207,000,000.00
- SNY $54,031,898,261.00
- Revenue This Year
- UBS N/A
- SNY $3.18
- Revenue Next Year
- UBS N/A
- SNY $6.67
- P/E Ratio
- UBS $21.06
- SNY $23.72
- Revenue Growth
- UBS 28.10
- SNY 6.01
- 52 Week Low
- UBS $26.01
- SNY $45.22
- 52 Week High
- UBS $33.34
- SNY $58.97
- Technical
- Relative Strength Index (RSI)
- UBS 30.73
- SNY 45.07
- Support Level
- UBS $31.66
- SNY $47.01
- Resistance Level
- UBS $32.33
- SNY $49.73
- Average True Range (ATR)
- UBS 0.38
- SNY 0.73
- MACD
- UBS -0.30
- SNY 0.16
- Stochastic Oscillator
- UBS 5.97
- SNY 48.60
About UBS UBS Group AG Registered
The core of UBS is its global wealth management business focusing on high and ultra-high-net-worth individuals. UBS is also a conventional retail and commercial bank in its Swiss home market. Its investment bank and asset management businesses support its wealth management operations, but also leverage its strength in wealth management to serve third-party clients.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.